Can paroxetine cause thrombocytopenia? Paroxetine is a medication that is used to treat depression, anxiety and panic disorders. Paroxetine is in the class of medications called SSRIs that work by preventing serotonin from being reabsorbed into the nerve cells of the brain.
This action allows for prolonging the mood lightening effects of serotonin and helps relieve the symptoms associated with your condition. The prescribing information on paroxetine lists a decreased number of platelets as a very rare side effect of the medication, occurring in 1 out of 10, patients.
The most common side effects are dry mouth, constipation, nausea, drowsiness, insomnia, headache, dizziness, yawning and weight gain.
You can browse Drugs A-Z for a specific prescription or over-the-counter drug or look up drugs based on your specific condition. This information is for educational purposes only, and not meant to provide medical advice, treatment, or diagnosis. Remember to always consult your physician or health care provider before starting, stopping, or altering a treatment or health care regimen.
No reports involved the administration of methylene blue by other routes such as oral tablets or local tissue injection or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Paxil. If concomitant use of Paxil with certain other serotonergic drugs, i. Treatment with Paxil and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
Potential Interaction With Thioridazine: Thioridazine administration alone produces prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsade de pointes—type arrhythmias, and sudden death. This effect appears to be dose related. An in vivo study suggests that drugs which inhibit CYP2D6, such as paroxetine, will elevate plasma levels of thioridazine. Epidemiological studies have shown that infants exposed to paroxetine in the first trimester of pregnancy have an increased risk of congenital malformations, particularly cardiovascular malformations.
The findings from these studies are summarized below: No increase in the risk of overall congenital malformations was seen in the paroxetine-exposed infants. The cardiac malformations in the paroxetine-exposed infants were primarily ventricular septal defects VSDs and atrial septal defects ASDs.
Septal defects range in severity from those that resolve spontaneously to those which require surgery. This study showed a trend towards an increased risk for cardiovascular malformations for paroxetine risk of 1. Of the 12 paroxetine-exposed infants with cardiovascular malformations, 9 had VSDs. In one study the odds ratio was 2.
Other studies have found varying results as to whether there was an increased risk of overall, cardiovascular, or specific congenital malformations. While subject to limitations, this meta-analysis suggested an increased occurrence of cardiovascular malformations prevalence odds ratio [POR] 1. It was not possible in this meta-analysis to determine the extent to which the observed prevalence of cardiovascular malformations might have contributed to that of overall malformations, nor was it possible to determine whether any specific types of cardiovascular malformations might have contributed to the observed prevalence of all cardiovascular malformations.
If a patient becomes pregnant while taking paroxetine, she should be advised of the potential harm to the fetus. Discontinuation of Treatment With Paxil. For women who intend to become pregnant or are in their first trimester of pregnancy, paroxetine should only be initiated after consideration of the other available treatment options.
These studies have revealed no evidence of teratogenic effects. The cause of these deaths is not known. Neonates exposed to Paxil and other SSRIs or serotonin and norepinephrine reuptake inhibitors SNRIs , late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying.
PPHN occurs in 1 — 2 per 1, live births in the general population and is associated with substantial neonatal morbidity and mortality. Other studies do not show a significant statistical association. Physicians should also note the results of a prospective longitudinal study of pregnant women with a history of major depression, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission.
Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their major depression compared to those women who remained on antidepressant medication throughout pregnancy. When treating a pregnant woman with Paxil, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating depression with an antidepressant.
During premarketing testing, hypomania or mania occurred in approximately 1. In a subset of patients classified as bipolar, the rate of manic episodes was 2. As with all drugs effective in the treatment of major depressive disorder, Paxil should be used cautiously in patients with a history of mania.
During premarketing testing, seizures occurred in 0. Paxil should be used cautiously in patients with a history of seizures. It should be discontinued in any patient who develops seizures. Discontinuation of Treatment With Paxil: Abnormal dreams, paresthesia, and dizziness. In the majority of patients, these events were mild to moderate and were self-limiting and did not require medical intervention.
During marketing of Paxil and other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon the discontinuation of these drugs particularly when abrupt , including the following: Dysphoric mood, irritability, agitation, dizziness, sensory disturbances e.
While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with Paxil. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible.
If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.
Pediatric Use , for adverse events reported upon discontinuation of treatment with Paxil in pediatric patients. However, other studies have failed to demonstrate such a risk. It is uncertain whether the coadministration of paroxetine and tamoxifen has a significant adverse effect on the efficacy of tamoxifen. One study suggests that the risk may increase with longer duration of coadministration.
When tamoxifen is used for the treatment or prevention of breast cancer, prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition. The use of paroxetine or other SSRIs has been associated with the development of akathisia, which is characterized by an inner sense of restlessness and psychomotor agitation such as an inability to sit or stand still usually associated with subjective distress.
This is most likely to occur within the first few weeks of treatment. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion SIADH.
Discontinuation of Paxil should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.
Do not crush, chew, or break an extended-release Paxil tablet. Swallow the tablet whole. Shake the oral suspension liquid well just before you measure a dose.
Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one. It may take up to 4 weeks before your symptoms improve. Keep using the medication as directed and tell your doctor if your symptoms do not improve.
Do not stop using Paxil suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to safely stop using this medicine. Follow your doctor's instructions about tapering your dose.
Store at room temperature away from moisture, heat, and light. Dosage Information in more detail What happens if I miss a dose? Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose. What happens if I overdose? Seek emergency medical attention or call the Poison Help line at An overdose of paroxetine can be fatal.
What should I avoid while taking Paxil?
Tags: kamagra 100 milligrams preise doxycycline for dog heartworm treatment can i take codeine with wellbutrin generic drug for wellbutrin sr sleeping pill with benadryl
© Copyright 2017 Why paxil is ordered / 45.64.132.41.